Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 100

Sort by

Sort Order Select

Journal Articles

A Novel Segmentation-Based Purity-Informed Approach Accurately Detects Total Copy Number and Its Subclonal Fraction in Myeloma Targeted Panel Sequencing Data

Naser Ansari-Pour, Mohammad Kazeroun, Seyed Alireza Hasheminasab, Emma J Lyon, Bethan Hudson-Lund, Evie Fitzsimons, Gaurav Agarwal, Kara-Louise Royle, Matthew W. Jenner, Martin F Kaiser, Karthik Ramasamy, Kwee Yong, Eileen M Boyle, Sarah Gooding, Angela Hamblin, Anjan Thakurta

Blood (2024) 144 (Supplement 1): 1909.

https://doi.org/10.1182/blood-2024-207973

Published: 2024

Journal Articles

Risk Assignment Using the Myeloma Genome Project Panel: A Comparison to Standard of Care Genetic Testing within the UK-MRA RADAR Trial

Blood (2024) 144 (Supplement 1): 3333.

https://doi.org/10.1182/blood-2024-209772

Published: 2024

Journal Articles

KLF5 Is a Key Regulator of IMiD-Induced Neutropenia

Blood (2024) 144 (Supplement 1): 2527.

https://doi.org/10.1182/blood-2024-207135

Published: 2024

Journal Articles

Constructing a Computational Workflow for the Identification of Novel Cellular and Molecular Drivers of Human Granulopoiesis

Blood (2024) 144 (Supplement 1): 2525.

https://doi.org/10.1182/blood-2024-207224

Published: 2024

Journal Articles

A Mass Cytometry-Based Clinical Pharmacodynamic Assay for Histone 3 Lysine 36 Dimethyl (H3K36me2) Levels in Myeloma Cells and Peripheral Blood for Implementation in NSD2 Inhibitor Ktx-1001 First in Human Trial in Relapsed and Refractory Multiple Myeloma

Joao Lourenco, Erin Flynt, Warren Baker, Edmund Watson, Udo Oppermann, Seyed Alireza Hasheminasab, Vicki Gamble, Benjamin Winograd, Anjan Thakurta

Blood (2024) 144 (Supplement 1): 6814.

https://doi.org/10.1182/blood-2024-201554

Published: 2024

Journal Articles

Development of a Spatial Multiomics Platform to Integrate Genomic, Transcriptomic and Proteomic Features for Translational Research in Multiple Myeloma

Sarah Gooding, Chen-Yi Wang, Warren Baker, Edmund Watson, Simon Davis, Roman Fischer, Oliver McCallion, Joanna Hester, Fadi Issa, Srinivasa Rao, Nick Athanasou, Anjan Thakurta, Karthik Ramasamy, Chad C. Bjorklund, Michael Amatangelo, Anita K. Gandhi, Adam P Cribbs, Alessandro Lagana, Udo Oppermann

Blood (2024) 144 (Supplement 1): 6848.

https://doi.org/10.1182/blood-2024-205264

Published: 2024

Journal Articles

Mezigdomide Treatment in Relapsed-Refractory Myeloma Patients Shifts Bone Marrow NK and T Cell Populations from Exhaustion to Activation

Lucia Y Chen, Oliver Van Oekelen, Michael Amatangelo, Tracy T. Chow, Bhaskar Upadhyaya, Alessandro Lagana, Geoffrey Kelly, Seunghee Kim-Schulze, Adolfo Aleman, Antonina Kurtova, Sarah Gooding, Sundar Jagannath, Erin Flynt, Anita K. Gandhi, Udo Oppermann, Anjan Thakurta, Samir Parekh

Blood (2023) 142 (Supplement 1): 4686.

https://doi.org/10.1182/blood-2023-187748

Published: 2023

Journal Articles

Acquisition of 1pLOH-1qGain Is a Frequent Trajectory in Expanding Relapsed/Refractory Myeloma Subclones

Naser Ansari-Pour, Mohammad Kazeroun, Evie Fitzsimons, Selina J Chavda, Alessandro Lagana, Erin Flynt, Udo Oppermann, Karthik Ramasamy, Kwee Yong, Sarah Gooding, Anjan Thakurta

Blood (2023) 142 (Supplement 1): 1999.

https://doi.org/10.1182/blood-2023-190584

Published: 2023

Journal Articles

A Multiomic Single-Cell Atlas of Human Myelopoiesis Reveals Cellular and Molecular Drivers of Immunomodulatory Drug-Induced Neutropenia

Christina Simoglou Karali, Simone Riva, Sally-Ann Clark, Sean Wen, Nikolaos Sousos, Eleni Louka, E. Ravza Gür, Nawshad Hayder, William E. Pierceall, Anjan Thakurta, Anita K. Gandhi, Patrick R Hagner, Jim Hughes, Adam J Mead

Blood (2023) 142 (Supplement 1): 935.

https://doi.org/10.1182/blood-2023-182041

Published: 2023

Journal Articles

Targeted NGS Panel Guides Risk-Adapted Treatment Intention in Newly Diagnosed Myeloma Patients

Gaurav Agarwal, Mohammad Kazeroun, Mirian Salazar, Khrystal McBean, Lisa Ferguson, Jemma Larham, Jaimal Kothari, Naser Ansari-Pour, Sally Moore, Eileen Boyle, Udo Oppermann, Karthik Ramasamy, Angela Hamblin, Anjan Thakurta, Sarah Gooding

Blood (2023) 142 (Supplement 1): 644.

https://doi.org/10.1182/blood-2023-182734

Published: 2023

Journal Articles

High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myeloma

Mehmet Kemal Samur, Marco Roncador, Anil Aktas Samur, Mariateresa Fulciniti, Abdul Hamid Bazarbachi, Raphael Szalat, Masood A. Shammas, Adam S. Sperling, Paul G. Richardson, Florence Magrangeas, Stephane Minvielle, Aurore Perrot, Jill Corre, Philippe Moreau, Anjan Thakurta, Giovanni Parmigiani, Kenneth C. Anderson, Hervé Avet-Loiseau, Nikhil C. Munshi

Blood (2023) 141 (14): 1724–1736.

https://doi.org/10.1182/blood.2022017094

Published: 2023

Includes: Supplemental data

Journal Articles

The location of the t(4;14) translocation breakpoint within the NSD2 gene identifies a subset of patients with high-risk NDMM

Nicholas Stong, María Ortiz-Estévez, Fadi Towfic, Mehmet Samur, Amit Agarwal, Jill Corre, Erin Flynt, Nikhil Munshi, Hervé Avet-Loiseau, Anjan Thakurta

Blood (2023) 141 (13): 1574–1583.

https://doi.org/10.1182/blood.2022016212

Published: 2023

Includes: Supplemental data

Journal Articles

Whole-genome analysis identifies novel drivers and high-risk double-hit events in relapsed/refractory myeloma

Naser Ansari-Pour, Mehmet Samur, Erin Flynt, Sarah Gooding, Fadi Towfic, Nicholas Stong, Maria Ortiz Estevez, Konstantinos Mavrommatis, Brian Walker, Gareth Morgan, Nikhil Munshi, Herve Avet-Loiseau, Anjan Thakurta

Blood (2023) 141 (6): 620–633.

https://doi.org/10.1182/blood.2022017010

Published: 2023

Includes: Supplemental data

Journal Articles

Suppression of Myeloid Cell-Derived Proinflammatory Cytokines with Celmod Agents: Implications for CRS with T-Cell Engagers (TCEs)

Danny V Jeyaraju, Maryam Alapa, Aimee O'Donohue, Ross La Motte-Mohs, Isaac W. Boss, Patrick Hagner, Michael Pourdehnad, Michael R. Burgess, William E. Pierceall, Anjan Thakurta

Blood (2022) 140 (Supplement 1): 7070–7071.

https://doi.org/10.1182/blood-2022-157927

Published: 2022

Journal Articles

Loss of COP9 signalosome genes at 2q37 is associated with IMiD resistance in multiple myeloma

Sarah Gooding, Naser Ansari-Pour, Mohammad Kazeroun, Kubra Karagoz, Ann Polonskaia, Mirian Salazar, Evie Fitzsimons, Korsuk Sirinukunwattana, Selina Chavda, Maria Ortiz Estevez, Fadi Towfic, Erin Flynt, William Pierceall, Daniel Royston, Kwee Yong, Karthik Ramasamy, Paresh Vyas, Anjan Thakurta

Blood (2022) 140 (16): 1816–1821.

https://doi.org/10.1182/blood.2022015909

Published: 2022

Includes: Supplemental data

Journal Articles

Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine

Hartmut Döhner, Andrew H. Wei, Gail J. Roboz, Pau Montesinos, Felicitas R. Thol, Farhad Ravandi, Hervé Dombret, Kimmo Porkka, Irwindeep Sandhu, Barry Skikne, Wendy L. See, Manuel Ugidos, Alberto Risueño, Esther T. Chan, Anjan Thakurta, C.L. Beach, Daniel Lopes de Menezes

Blood (2022) 140 (15): 1674–1685.

https://doi.org/10.1182/blood.2022016293

Published: 2022

Includes: Supplemental data

Journal Articles

Overcoming IMiD resistance in T-cell lymphomas through potent degradation of ZFP91 and IKZF1

Blood (2022) 139 (13): 2024–2037.

https://doi.org/10.1182/blood.2021014701

Published: 2022

Includes: Supplemental data

Journal Articles

Discovery of Prolyl-tRNA Synthetase As a Novel Target in Multiple Myeloma

Blood (2021) 138 (Supplement 1): 890.

https://doi.org/10.1182/blood-2021-148536

Published: 2021

Journal Articles

Repressed Chromatin Drives Leukaemogenesis in Mutant IDH2 Acute Myeloid Leukaemia Via Inhibition of Granulocyte Differentiation and Cell Cycle Progression

Douglas RA Silveira, Prodromos Chatzikyriakou, Olena Yavorska, Sarah Mackie, Roan Hulks, Paulina Siejka-Zielinska, Anna Corby, Alastair Smith, Benjamin Brown, Marlen Metzner, Thomas A. Milne, Virginie Penard-Lacronique, Chunxiao Song, Maroof Hasan, Anjan Thakurta, Paresh Vyas, Skirmantas Kriaucionis, Lynn Quek

Blood (2021) 138 (Supplement 1): 3467.

https://doi.org/10.1182/blood-2021-149519

Published: 2021

Journal Articles

Super-Enhancer Driven Regulation of CKS1B in Multiple Myeloma: Implications in Mediating Response to BET Inhibitor and Celmod Agent Combination

Aarif Ahsan, Ann Polonskaia, Chih-Chao Hsu, Chad C Bjorklund, Maria Ortiz Estevez, Fadi Towfic, Nizar J. Bahlis, Michael Pourdehnad, Erin Flynt, Aarif Ahsan, Anjan Thakurta

Blood (2021) 138 (Supplement 1): 2658.

https://doi.org/10.1182/blood-2021-150641

Published: 2021

NARROW

A Novel Segmentation-Based Purity-Informed Approach Accurately Detects Total Copy Number and Its Subclonal Fraction in Myeloma Targeted Panel Sequencing Data

Risk Assignment Using the Myeloma Genome Project Panel: A Comparison to Standard of Care Genetic Testing within the UK-MRA RADAR Trial

KLF5 Is a Key Regulator of IMiD-Induced Neutropenia

Constructing a Computational Workflow for the Identification of Novel Cellular and Molecular Drivers of Human Granulopoiesis

A Mass Cytometry-Based Clinical Pharmacodynamic Assay for Histone 3 Lysine 36 Dimethyl (H3K36me2) Levels in Myeloma Cells and Peripheral Blood for Implementation in NSD2 Inhibitor Ktx-1001 First in Human Trial in Relapsed and Refractory Multiple Myeloma

Development of a Spatial Multiomics Platform to Integrate Genomic, Transcriptomic and Proteomic Features for Translational Research in Multiple Myeloma

Mezigdomide Treatment in Relapsed-Refractory Myeloma Patients Shifts Bone Marrow NK and T Cell Populations from Exhaustion to Activation

Acquisition of 1pLOH-1qGain Is a Frequent Trajectory in Expanding Relapsed/Refractory Myeloma Subclones

A Multiomic Single-Cell Atlas of Human Myelopoiesis Reveals Cellular and Molecular Drivers of Immunomodulatory Drug-Induced Neutropenia

Targeted NGS Panel Guides Risk-Adapted Treatment Intention in Newly Diagnosed Myeloma Patients

High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myeloma

The location of the t(4;14) translocation breakpoint within the NSD2 gene identifies a subset of patients with high-risk NDMM

Whole-genome analysis identifies novel drivers and high-risk double-hit events in relapsed/refractory myeloma

Suppression of Myeloid Cell-Derived Proinflammatory Cytokines with Celmod Agents: Implications for CRS with T-Cell Engagers (TCEs)

Loss of COP9 signalosome genes at 2q37 is associated with IMiD resistance in multiple myeloma

Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine

Overcoming IMiD resistance in T-cell lymphomas through potent degradation of ZFP91 and IKZF1

Discovery of Prolyl-tRNA Synthetase As a Novel Target in Multiple Myeloma

Repressed Chromatin Drives Leukaemogenesis in Mutant IDH2 Acute Myeloid Leukaemia Via Inhibition of Granulocyte Differentiation and Cell Cycle Progression

Super-Enhancer Driven Regulation of CKS1B in Multiple Myeloma: Implications in Mediating Response to BET Inhibitor and Celmod Agent Combination

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only